Spikevax (previously COVID-19 Vaccine Moderna) Európai Unió - magyar - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - a vakcinák - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics Európai Unió - magyar - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - az a / vietnam / 1194/2004 (h5n1) törzs influenzavírus-felületi antigénjei (hemagglutinin és neuraminidáz) - influenza, human; immunization; disease outbreaks - a vakcinák - aktív immunizálás az influenza a vírus h5n1 altípusa ellen. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

COVID-19 Vaccine (inactivated, adjuvanted) Valneva Európai Unió - magyar - EMA (European Medicines Agency)

covid-19 vaccine (inactivated, adjuvanted) valneva

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - a vakcinák - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Zoonotic Influenza Vaccine Seqirus Európai Unió - magyar - EMA (European Medicines Agency)

zoonotic influenza vaccine seqirus

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - a vakcinák - active immunisation against h5 subtype of influenza a virus.

BCG VACCINE AJV por és oldószer szuszpenziós injekcióhoz Magyarország - magyar - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

bcg vaccine ajv por és oldószer szuszpenziós injekcióhoz

aj vaccines a/s - vakcina (bakteriális) -

Pandemic Influenza Vaccine H5N1 Baxter AG Európai Unió - magyar - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 baxter ag

resilience biomanufacturing ireland limited - influenza vakcina (teljes virion, inaktivált), amely az alábbi antigént tartalmazta: a / vietnam / 1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - a vakcinák - az influenza profilaxisa a hivatalosan bejelentett pandémiás helyzetben. a pandémiás influenza vakcinát a hivatalos útmutatásnak megfelelően kell használni.

Nobivac Piro Európai Unió - magyar - EMA (European Medicines Agency)

nobivac piro

intervet international bv - babesia canis, inactivated, babesia rossi, inactivated - immunológiai állományok kanidákhoz - kutyák - hat hónapos vagy idősebb kutyák aktív immunizálására a babesia canis ellen az akut babesiózis (b. canis) és a vérszegénységgel, a csomagolt sejtek térfogatával mérve. a védettség kezdete: három hét az alap vakcinázás után. a mentesség időtartama: hat hónappal az utolsó (újra) oltás után.

PreHevbri Európai Unió - magyar - EMA (European Medicines Agency)

prehevbri

vbi vaccines b.v. - hepatitis b felületi antigén - hepatitisz b - a vakcinák - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Jcovden (previously COVID-19 Vaccine Janssen) Európai Unió - magyar - EMA (European Medicines Agency)

jcovden (previously covid-19 vaccine janssen)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - a vakcinák - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. használja ezt a vakcinát a hivatalos ajánlásoknak megfelelően.

Focetria Európai Unió - magyar - EMA (European Medicines Agency)

focetria

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - influenza vakcinák - a (h1n1v) 2009 vírus által okozott influenza profilaxisa. a focetria-t kell használni, hivatalos ajánlásoknak megfelelően.